Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals

Affiliations

¹ Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
² Global Health Institute, University of Antwerp, Campus Drie Eiken, Gouverneur Kinsbergencentrum, Wilrijk, Belgium.

Editorial

Bin Su et al. AIDS. 2023.

. 2023 Apr 1;37(5):837-839.

doi: 10.1097/QAD.0000000000003492.

¹ Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
² Global Health Institute, University of Antwerp, Campus Drie Eiken, Gouverneur Kinsbergencentrum, Wilrijk, Belgium.

No abstract available

Comment on

Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad E, Moran-Garcia N, Datwani S, Duncan MC, Kalikawe R, Ennis S, Young L, Ganase B, Omondi FH, Umviligihozo G, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. Lapointe HR, et al. AIDS. 2023 Apr 1;37(5):709-721. doi: 10.1097/QAD.0000000000003469. Epub 2022 Dec 22. AIDS. 2023. PMID: 36545783 Free PMC article.

1. Oyelade T, Alqahtani JS, Hjazi AM, Li A, Kamila A, Raya RP. Global and regional prevalence and outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis . Trop Med Infect Dis 2022; 7:22.
1. Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study . Lancet HIV 2021; 8:e554–e567.
1. Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape . Cell Host Microbe 2022; 30:154–162.
1. Mandala WL, Liu MKP. SARS-CoV-2 and HIV-1: should HIV-1-infected individuals in sub-Saharan Africa be considered a priority group for the COVID-19 vaccines? . Front Immunol 2021; 12:797117.
1. Yin J, Chen Y, Li Y, Wang C, Zhang X. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis . Int J Infect Dis 2022; 124:212–223.